MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Statement of Purpose
Guidelines for Authors
Editorial Board

Recent Issues

November 2008


Cover Story

Heparin-Induced Thrombocytopenia: Overview and Treatment

Heparin is a valuable anticoagulant, but it can induce severe immunologic ­reactions at any dose. The authors present a comprehensive review of the pathophysiology, etiology, diagnosis, laboratory findings, and therapeutic management of thrombocytopenia that can result from this antithrombotic agent.
Daniel A. Zinkovsky, PharmD, and Marilena S. Antonopoulos, PharmD, FASCP

Medication Utilization Patterns and Hypertension-Related Expenditures among Patients Who Were Switched from Fixed-Dose To Free-Combination Antihypertensive Therapy

In an evaluation of patients who were switched from fixed-dose combination (FDC) to free-combination (FC) therapy for elevated blood pressure, the authors found that patients continuing with the FDC regimen had better persistence and compliance compared with patients who were switched to FC therapy. Greater compliance with the FDC regimen was also associated with lower health care costs and with less use of health care–related resources.
Gregory Hess, MD, MBA; Jerrold Hill, PhD; Helen Lau, MS; Homa Dastani, PhD; and Paresh Chaudhari, PharmD, MPH

Meeting Highlights

European Society for Medical Oncology and Association for the Study of Bone and Mineral Research

Some of the topics covered at this oncology meeting included cetuximab (Erbitux) for colorectal cancer, pazopanib and antibody CP-751871 for non–small-cell lung cancer; Everolimus (Certican) for pancreatic tumors; lapatinib (Tykerb) for squamous cell carcinoma; and Elesclomol for melanoma. Denosumab and odanacatib, presented at the bone and mineral research meeting, were found to increase bone density and build new bone.
Walter Alexander

Pharmaceutical Approval Update

Romiplostim (Nplate) for thrombocytopenia; palonosetron capsules (Aloxi) for chemotherapy-induced nausea and vomiting; and iobenguane iodine-123 injection (AdreView), used for diagnosing primary or metastatic pheochromo­cytoma or neuroblastoma as an adjunct to other tests, are discussed.
Marvin M. Goldenberg, PhD, RPh, MS



Moody’s Musings

David Nash, MD, MBA, muses on the gloomy mood of Moody’s Investor Services.
David B. Nash, MD, MBA

Medication Errors

Oops, Sorry, Wrong Patient!
Applying the Joint Commission’s “Two-Identifier” Rule Goes beyond the Patient’s Room

Matthew Grissinger, RPh, FASCP, explains how the Joint Commission’s “two-identifer” rule can help prevent patient mixups.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

DEA Opens the Door to e-Prescribing of Controlled Substances

Stephen Barlas discusses the Drug Enforcement Agency’s proposal to allow electronic prescribing of Schedule II–V controlled substances in order to reduce diversion of these agents.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Cinryze to Vaprisol, P&T presents the latest information about FDA approvals, new indications, recalls, and industry updates.

Drug Forecast

Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)

Authors Kisgen and Whitney review ceftobiprole, a cephalosporin for methicillin-resistant Staphylococcus aureus (MRSA) infection.
Jamie Kisgen, PharmD, and Dana Whitney, PharmD, BCPS